SOURCE: NuLife Sciences, Inc.

NuLife Sciences, Inc. Logo

August 15, 2017 08:30 ET

NuLife Announces Pre-Clinical Trial of NuLife Technique

NEWPORT BEACH, CA--(Marketwired - August 15, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced that it is initiating a pre-clinical trial on the NuLife Technique, a means to potentially eliminate the need for organ or tissue matching between donor and recipient in organ transplants and the necessity for anti-rejection drugs after surgery.

The trial, commenced on August 8th at Florida International University, and will evaluate the NuLife process in an autologous setting, meaning an organ is removed from and transplanted back to the same donor. The objective of the study is to prove that the NuLife Technique is viable.

This first of a series of pre-clinical trials, a kidney will be removed from a pig, the NuLife Technique will be applied to the kidney, and it will be transplanted back into the original "donor" pig. Two weeks after the transplant, both kidneys (the control kidney left in the animal and the kidney that had the NuLife Process applied) will be histologically compared. Results from the trial will be published as a series, with findings presented as each step of the pre-clinical work is completed.

The surgeries are being conducted at the Florida International University (FIU) under the sponsorship of the FIU Chair of Surgery, Jaime Rodriguez, MD, Associate Professor of Surgery. Our two lead investigators and transplant surgeons, Dr. Arenas and Dr. Hranjec performed the first set of experiments. Juan Arenas, MD, FACS, MBA, is a board-certified transplant surgeon, Director of the Solid Organ Transplant Institute, and the Chair of Solid Organ Transplant at Memorial Regional Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at the University of Texas (UT) Southwestern Medical Center for the past 10 years. Tjasa Hranjec, MD, MS-CR is a Board certified trauma/critical care and transplant surgeon, the director of the Transplant Intensive Care Unit at the Memorial Regional Hospital in Hollywood. The NuLife process is being conducted in the science laboratory at Nova Southeastern University.

"After 15 years of committed research conducted on this technology, we're thrilled to begin this potentially groundbreaking study into what we believe represents an entirely next generation of novel, patent-protected organ transplantation science and hematopoietic research," said John Hollister, NuLife Sciences Chief Executive Officer. We anticipate our pre-clinical work will provide valuable information that will validate our approach and move us closer to revolutionizing the field of kidney transplantation."

"With approximately 123,000 people on the candidate waiting list for a transplant in the US, but only about 31,000 organ transplants occurring every year," Mr. Hollister added, "the NuLife Process has the potential to save lives, significantly improve the quality of life, while saving significant costs on the healthcare system."

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation, regenerative medicine, cell therapy, organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

Contact Information